Edition:
United Kingdom

Profile: Apollo Endosurgery Inc (APEN.OQ)

APEN.OQ on NASDAQ Stock Exchange Global Market

3.55USD
9:00pm BST
Change (% chg)

$0.15 (+4.41%)
Prev Close
$3.40
Open
$3.43
Day's High
$3.55
Day's Low
$3.43
Volume
684
Avg. Vol
4,057
52-wk High
$9.56
52-wk Low
$3.05

Apollo Endosurgery, Inc., formerly Lpath, Inc., incorporated on September 18, 2002, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company's device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.

The Company's products include ORBERA, LAP-BAND and OverStitch. The Company's product, ORBERA, is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract, including closing Fistulas, Endoscopic Submucosal Dissections (ESDs), Endoscopic Mucosal Resections (EMRs), and Peroral Endoscopic Myotomy (POEM) procedures. Additionally, physicians are leveraging endoscopic suturing for a range of bariatric procedures, including Endoscopic Sleeve Gastroplasty (ESG), Bariatric Sleeve Revisions, Outlet and Pouch Reductions.

Company Address

Apollo Endosurgery Inc

1120 South Capital Of Tx Hwy
Building 1 Suite 300
WEST LAKE HILLS   TX   78746-6464
P: +1512.2795100
F: +1302.6745266

Company Web Links